AGREENA
30.3.2023 08:01:28 CEST | Business Wire | Press release
Climate and fintech company Agreena, whose soil carbon platform is one of the largest globally, today announced its Series B raise of €46M. Led by Germany’s leading multi-stage investor HV Capital, the round has an exciting composition of new investors including impact fund AENU and fintech-focused Anthemis. The equity raise is also supported by a doubling-down from existing shareholders, including evergreen food investor Gullspång Re:food, well-established tech investor Kinnevik and Denmark’s Export and Investment fund.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005976/en/
Agriculture-based carbon removals are considered one of the most readily available and easily scaled solutions for climate change mitigation (Photo: Business Wire)
The sizable raise comes just one year after the company’s €20M Series A. Since then, Agreena has scaled its activities 10X, expanded its geographic footprint to cover farmland in 16 European countries, and partnered with farms to help them transition more than 600,000 hectares towards climate-positive, regenerative farming.
“In order for the world’s farmers to transition to regenerative agriculture and create a scalable climate impact, the financial rails to support and pay them for it need to be built,” said Simon Haldrup, Co-founder and CEO of Agreena. “Agreena is building out technological and financial services infrastructure throughout the agriculture value chain as the industry increasingly becomes a focal point for decarbonisation efforts.”
Momentum around regenerative farming is sweeping the globe, with corporates, governments and supply chains turning their focus to our agricultural soils for carbon removals in order to meet global net-zero targets. Through the adoption of regenerative agriculture practices, farmers will play an increasingly essential role in tackling climate change, food insecurity, and other critical environmental issues. Agreena has developed a way to turn this impact into a new and additional revenue stream for farmers to help finance the transition by leveraging the carbon market.
Via the company’s digital platform, farmers plan, track and validate improvements for their regenerative journey, in the process transitioning from emitting CO2 to drawing CO2 down and storing it within their soils. The improved soil health and biodiversity reduce the need for inputs while enhancing farmers’ resilience to increasingly adverse climate conditions (such as drought or flooding), enhancing the overall operational performance of farms. On the other side of the equation, Agreena’s certificates and downstream services support climate-focused companies already working to decarbonise, as well as companies in the food supply chain increasingly requiring field-level traceability of their agricultural commodities to comply with Scope 3 reporting requirements.
Scaling with Technology
The recent acquisition of remote sensing company Hummingbird Technologies has enabled Agreena to expand its offering beyond farmers to encompass agridata services for supply chain players, governments and other institutions. Prioritising a science-based and technology-first agenda, Agreena’s platform now incorporates a world-leading, AI-based monitoring and verification solution that utilises satellite imagery, coupled with ground-truth data and machine learning to identify and report on-farm regenerative agriculture practices. Offering global monitoring, the company is on a mission to take the lead in supporting the road to net zero for the full value chain.
“Real climate impact is only created at scale and Agreena is perfectly positioned to distribute their carbon farming capabilities across the globe to bring high-quality, verifiable and nature-based carbon credits to the market. Only with carbon removals, can net zero targets be met,” said Alexander Joel-Carbonell, partner at HV Capital.
From Farmer to Fintech
Deeply rooted within the agricultural community, Agreena was originally founded with seed investment from Danish farmers and agricultural families. The company’s next phase introduces a vertically integrated platform and marketplace. Working first with farmers in the field to monitor the carbon impact, the resulting certificates are constructed into scalable portfolios for corporates, tailored to their unique ESG strategy.
The company is taking a lead in providing the technological rails for the growing market with innovative financial solutions. Examples include using sustainable blockchain technology for enhanced traceability and transparency of carbon credits, and e-money and smart contracts to facilitate payment exchanges between climate-conscious corporates and farmers with immediate reconciliation at scale.
“We are on a journey to remove the economic barriers to adoption of regenerative agriculture for farmers and their entire ecosystem - carbon is just the beginning,” concluded Haldrup.
About Agreena
Agreena unlocks the power of soil carbon removals and natural capital to finance the transition to regenerative agriculture. Working in close collaboration with partner farmers across 16 European markets and growing, AgreenaCarbon is the world’s leading soil carbon platform. Combined with market leading satellite monitoring technologies, Agreena’s solutions can support farmers, companies, and governments on the road to net zero.
About Agreena’s Carbon Certification
Agreena’s programme is accredited to the ISO 14064-2 standard, with a third-party verified methodology that is aligned to IPCC science. The company is standards-inclusive and will continue to evolve its offering as policies and science continue to develop. Further, the company is currently undergoing certification with Verra, completion of the process is expected later this year.
About HV Capital
HV Capital is one of the most successful and financially strongest early-stage and growth investors in Europe. Since 2000, HV Capital has invested in around 225 internet and technology companies such as Zalando, Delivery Hero, Flixbus, and HelloFresh through various generations of funds and is continuously looking for the next generation of disruptors from every industry, including FinTech, SaaS, climate tech, and consumer goods. The company supports startups with capital between €500,000 to €50 million and is one of the few venture capital firms in Europe that can finance startups through all growth phases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005976/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom